Recent advances in the grafting of burns and giant congenital nevi include cultured epithel i~m , ' -~ alone or in combination with biopolymer or allodermis.'** However, incomplete epidermal barrier and lack of vascular and immune components at grafting make all modelsg-' of cultured skin more subject to destruction by burn organisms than native skin grafts. These biologic deficiencies also make cultured epidermal keratinocytes more subject to cytotoxicity of topical antimicrobial agents. Most parenteral antimicrobial drugs are effective and have low toxicity, but topical use may induce resistant organisms that complicate treatment of sepsis. Therefore, requirements for topical antimicrobial agents for cultured skin include: (1) low toxicity to cultured human skin cells; (2) high activity against common burn wound organisms; and (3) no overlap of activity with parenteral drugs. Assays for drugs that meet these requirements have tested cytotoxicity to cultured human fibroblasts12 or keratinocytes,13 antimicrobial activity,14-l6 or combinations of fibroblasts and burn organism^.'^-'^ This report describes a combined cytotoxicity-antimicrobial assay system in which candidate agents may be tested for toxicity to cultured human epidermal keratinocytes and fibroblasts, and also for antimicrobial activity to common burn wound organisms. Three antibiotics (amikacin, piperacillin, norfloxacin), an antimycotic (nystatin), and an antiseptic (Hibiclens) were tested, alone and in combination, on cultured cells and four isolates each of burn organisms (Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter sp., Escherichia coli, Candida sp. ). T h e data show that combinations of norfloxacin (25 pg/mL) plus nystatin (100 U/mL), or amikacin From the Shriners Burns Institute and Department of Surgery, University of Cincinnati, Cincinnati, Ohio. Presented at the 24th Annual Meeting of the American Burn Association, Salt Lake City, Utah, April 2, 1992 . Supported by Shriners Hospitals for Crippled Children, grants #I5893 and #15837. Received for publication March 27,1992; revised July 20, 1992. (1 50 pg/mL) plus piperacillin (300 pg/mL) plus nystatin (100 U/mL) are nontoxic to cultured human cells and effective against a broad spectrum of burn organisms. T h e data suggest that the combination of norfloxacin, a quinolone, with nystatin may have potential as a topical antimicrobial on cultured skin for burns. Figure 1 shows the procedural plan by which candidate antimicrobial agents are qualified as having no/low toxicity to cultured human skin cells, and antimicrobial activity to common burn wound organisms. This strategy for serial testing was developed from an initial protocol of parallel testing to reduce the number of tests required for each compound. After determination of the highest concentration that is not cytotoxic to cultured keratinocytes and fibroblasts, that concentration was tested for antimicrobial activity on representative samples of microorganisms. In this study, both serial and parallel testing of agents on cultured cells and microorganisms were performed, but serial testing as diagrammed in Figure l is recommended for efficiency. Table I lists the antimicrobial agents tested, the highest test concentration, and the pH and osmolarity. For human cell assays, each agent was diluted serially to 100-fold of the highest test dose into respective growth media at half-log concentrations. For antimicrobial assays, the highest concentration was tested on 24 clinical isolates of burn organisms (see below).
Experimental Design

Antimicrobial Agents
Human Cell Assay
Human epidermal keratinocytes and dermal fibroblasts were isolated from surgical discard tissue obtained with the approval of the University of Cincinnati Institutional Review Board. Epidermal keratinocytes were grown as described previously20. *' in serum-free MCDB 153 medium with 0.2 mM calcium and increased amino acids,4 and supplemented with 0.5% bovine pituitary extract, 1 ng/mL epidermal growth factor, 5 pg/mL insulin, and 0.5 pg/mL hydrocortisone. Dermal fibroblasts were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 1 ng/mL EGF, 5 pg/mL insulin, and 0.5 pg/mL hydrocortisone. Keratinocytes or fibroblasts were inoculated into petri dishes at 2 x l o 4 cells/dish into the respective culture media described above that also contained penicillin (1 00 U/mL)-streptomycin (1 00 pg/rnL)-amphotericin B (PSF) (0.25 pg/mL). Cells were incubated for 4 days at 3'7°C in 5% COP with saturated humidity. O n day 4, media were changed to remove PSF, baseline cell counts were performed, and test compounds were titrated into the cell cultures. Cells were incubated for 4 additional days and then harvested and counted. was performed in triplicate, and each experipared with cultures that received no drug. Anment was repeated once (n = 6; except Hibiclens, timicrobial agents tested in wet disc assays were n = 3). no/low toxicity to cultured cells and were effecpneumoniae, Enterobacter sp., E. coli, and Candida tive in the wet disc assay could be considered for sp. were isolated from wounds of burn patients at topical use with cultured skin. the Shriners Burns Institute, Cincinnati Unit. Petri dishes (1 50 x 15 mm) containing Mueller-RESULTS Hinton agar were inoculated by uniformly swabbing the plate surface with a suspension of each Human Cell Assays organism diluted to 0.5 McFarlane density units. Figure 2 shows that PSF or increased osmoSterile 6-mm filter paper discs, placed on the larity caused no significant reduction in growth microbial lawns, received 25 pL of the highest of human keratinocytes and fibroblasts. Hibitest dose of antimicrobial solution. Dishes were dens (Fig. 3 ) at concentrations as low as 0.5 perincubated at 37°C overnight, and the zone of cent (V/V) inhibited growth of both fibroblasts clearing was scored. '
and keratinocytes. Separate titrations of amikacin, piperacillin, or nystatin over two log diluData Collection, Analysis, and Interpretation tions caused no inhibition of growth of either Data collected from human cell assays were fibroblasts or keratinocytes (data not shown).
tested for significance ( p < 0.05, ANOVA) com- T e s t conditions were initiated o n culture day 4 (T). (1 50 pg/mL), piperacillin (300 pg/mL), and nyspg/mL or 75 pg/mL but not at lower concentatin (100 U/mL) had no toxicity to either fitrations. Keratinocytes (Fig. 5) were destroyed broblasts or keratinocytes. Norfloxacin (Fig. 5) by norfloxacin at 250 pg/mL in serum-free meinhibited significantly fibroblast growth at 250 dium but were not significantly inhibited at lower concentrations. Figure 6 shows that combination of 100 U/mL nystatin with norfloxacin at 25 pg/mL or less caused no significant inhibition of fibroblast or keratinocyte growth. Figure 7 shows cultured human keratinocytes with no inhibition of growth (7A) or cytotoxic response (7B), and fibroblasts with no growth inhibition (7C) or after exposure to 5% Hibiclens (70). Table I1 summarizes results of wet disc assays of 24 clinical isolates of microorganisms from burn wounds. Hibiclens was uniformly effective (24 of 24) against Although various models of cultured skin have been demonstrated to close wounds permanently,1,4,7 a11 are more subject to destruction by common burn organisms than are conventional skin grafts. This general limitation of cultured skin results from the incomplete epidermal barrier at grafting, the absence of vascular plexus and immune cells, and the consequent protraction of engraftment by several days. These bio- 
Wet Disc Assays
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logic deficiencies of cultured skin account for its vulnerability to microbial destruction and impose additional surgical and postsurgical requirements for protection of the cultured cells until epidermal tissue becomes keratinized. However, it has been s h o~n '~. '~,~~ that topical antimicrobial agents (i.e., mafenide acetate, silver sulfadiazine, Hibiclens) that are used successfully with native skin grafts are toxic to cultured keratinocytes and lead to failure of cultured grafts. Therefore, quantitative assays are needed to select antimicrobial agents in appropriate dosages that have no or low toxicity to transplanted cells, and that retain a broad spectrum of antimicrobial activity. T h e results presented here demonstrate a combined assay system for determination of concentration ranges of candidate drugs with a low toxicity to human cells and a high susceptibility to burn wound microorganisms.
This assay system can both qualify and disqualify either individual agents or combinations of agents for topical use. Although Hibiclens is uniformly effective against a wide variety of burn organisms, it is disqualified from consideration because it is also highly cytotoxic to cultured keratinocytes and fibroblasts (Fig. 3, Table 11 ). Conversely, norfloxacin is qualified as an antibiotic that has low toxicity to skin cells only within certain concentration ranges, but with retention of broad activity against burn organisms in those ranges (Fig. 5, Table 11 ). However, subsequent testing of norfloxacin at 25 pg/mL or less has identified strains of P. aureus and S. aureus that are not susceptible. Furthermore, the wet disc assay for antimicrobial activity determined that amikacin and piperacillin separately are not uniformly effective against assorted burn organisms but are effective together. These combined cytotoxicity-antimicrobial assays also identified that addition of an antimycotic agent, nystatin, to antibiotic formulations does not increase cytotoxicity to transplanted cells or reduce the antimicrobial activities of the individual agents. Therefore, these assays identify highly stringent requirements for selected antimicrobial agents for avoiding cytotoxicity to cultured skin. However, it is expected that as cultured skin substitutes are developed with more biologic homology to native skin (i.e., improved keratinization and barrier function), stringency for clinical management of cultured and native skin grafts may also become more homologous. Some other factors not addressed in this study that are important to clinical management of microbial contamination of cultured skin include: (1) nonoverlapping antimicrobial activity with parenteral treatment of burn sepsis; (2) delivery of adequate levels of antimicrobial formulations to the site of the microbial contamination; and (3) monitoring of contaminations of each patient to determine type and sensitivity of organisms to certain formulations. Amikacin and piperacillin are parenteral drugs used for treatment of sepsis and are not proposed here for topical use. They were included in this study to demonstrate the process by which candidate compounds are qualified for individual or combined administration. Norfloxacin at 25 pg/mL or less, in combination with 100 U/mL nystatin, meets this additional criteria for topical ~s e . '~,~~ Delivery of novel formulations to the site of contamination is a complex question that requires dedicated studies to address. T o understand and regulate drug delivery, future studies should address woundbed preparation and pretreatment, vehicles and protocols for administration of novel formulations, penetration and half-life of compounds in the wound, and effective dose at the graft-wound interface. Finally, monitoring of patient wounds to determine type and sensitivity of microbial contamination is a routine clinical procedure with which the cytotoxicityantimicrobial assays described here can be easily coordinated. Any novel formulations of topical antimicrobial^^^,^^ qualified by the assays described here may be added to the sensitivity testing of organisms for identification of whether the formulations are suitable for use with cultured skin in particular patient cases.
In conclusion, this study demonstrates a direct and inexpensive assay system by which topical antimicrobial agents may be selected for use with cultured skin grafts for burn wound treatment. Application of these findings may improve engraftment and survival of cultured skin for burns and may assist in the identification of qualified formulations of antimicrobial agents for management of other surgical infections.
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